ACE-083
Also known as: ACE-083
ACE-083 is a locally acting follistatin-based fusion protein designed to increase muscle size and strength in the specific muscle into which it is injected.
Last updated
Mechanism of Action
ACE-083 is a fusion of a modified follistatin domain with an IgG2 Fc region engineered for high local retention at the injection site. It sequesters myostatin (GDF-8), activin, and related TGF-beta ligands within the targeted muscle, blocking ActRIIB-mediated SMAD2/3 signaling. Because it is designed to stay localized rather than circulate systemically, it produces focal muscle hypertrophy in the injected muscle, which was studied for focal neuromuscular diseases.
- Half-life
- Engineered for prolonged local retention; systemic exposure minimal
- Administration Routes
- intramuscular
- Research Status
- Preclinical
Reported Benefits
- Produces localized, targeted muscle growth
- Increases muscle volume in the injected muscle
- Studied for focal muscle strength gains
- Investigated in facioscapulohumeral and Charcot-Marie-Tooth disease research
- Minimal intended systemic exposure
Potential Side Effects
- Injection-site pain and swelling
- Localized bruising
- Headache reported in trials
- Did not consistently translate muscle growth into functional improvement
- Unknown long-term safety
Common Dosing
For research use only; clinical trials administered fixed intramuscular doses (reported in the ~150 to 200 mg per muscle range) every few weeks. Nothing here is medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not for human or clinical use outside trials
- Pregnancy or breastfeeding
- Bleeding disorders
ACE-031
ACE-031 is a soluble decoy receptor (ActRIIB-Fc fusion) studied as a myostatin inhibitor to increase muscle mass and strength.
Follistatin 344
Follistatin 344 is the full-length precursor isoform of follistatin studied for blocking myostatin and activin to drive muscle growth and tissue repair.
- View
Locally acting ACE-083 increases muscle volume in healthy volunteers
2018
- View
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy
2022
- View
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
2022
- View
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease
2019